12:00 AM
 | 
Feb 16, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pixantrone regulatory update

Cell Therapeutics said it plans to begin a European named-patient program next quarter to allow patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL) to gain...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >